Itron, Inc. enters the post-earnings window with the stock pricing in disappointment after a weaker-than-expected Q1 print and a fresh round of analyst target cuts.
Q1 2026 results landed on April 28 and the market's reaction was swift. Revenue of $587 million came in below the year-ago quarter's $607 million. Net income fell to $53.5 million from $65.5 million a year earlier. EPS of $1.18 missed the prior-year $1.42. The stock fell nearly 5% on the day and has shed 7.8% across the week, trading at $82.69 as of April 29.
The options market had been flagging caution ahead of the print. Put/call ratio ran above its 20-day average for much of the week approaching earnings, sitting at 1.01 on April 29 versus a mean near 0.86 — modest defensiveness, about 1.1 standard deviations above normal. The caution was well-placed. What's notable post-result is that the borrow market shows no real stress. Cost to borrow is just 0.45%, barely moved on the week. Availability remains loose, with utilization around 16% against a 52-week high of 18%. There is no squeeze pressure here and no rush to cover.
Short interest tells a nuanced story. At 11.5% of free float, the short book is meaningful and has grown roughly 8% over the past month. But in the week running into earnings it actually declined — from about 5.4 million shares on April 23 to just under 5.15 million on April 28. FINRA's fortnightly figure puts settled short interest near 5.04 million shares with 8.95 days to cover. Shorts trimmed before the print, not after. Whether that was profit-taking ahead of a risky event or genuine covering remains to be seen, but positioning looks more cautious than aggressively bearish.
The Street is clearly adjusting. TD Cowen's Jeff Osborne cut his price target from $145 to $130 on April 29 — the same day the results landed — while keeping a Buy. JPMorgan trimmed from $133 to $113 mid-month, also maintaining Overweight. Oppenheimer bucked the trend with a slight nudge higher to $135. The consensus mean sits at $127.50, implying roughly 54% upside from current levels, though that gap looks partly mechanical — multiple analysts haven't yet reflected the Q1 miss. The bull case rests on software ARR momentum, a 24% run-rate growth projection, and early achievement of 2027 margin targets. Bears point to a 2024-2027 revenue CAGR now tracking negative and 2026 EBITDA forecasts moving lower. The EV/EBITDA multiple has drifted down to 10x, off roughly 3% over the past month, compressing with the price. EPS momentum factor ranks in the 22nd percentile on a 30-day view — near the bottom of the universe — and the forward EPS trajectory ranks only 5th percentile year-on-year, reflecting the deterioration in consensus estimates.
Institutional ownership offers little near-term drama. BlackRock holds 16.3% and added 167,000 shares as of end-March. Vanguard holds another 13.2%. These are passive-heavy positions — unlikely to shift quickly. The insider picture shows a concentrated cluster of sells on February 24, including CEO Thomas Deitrich offloading 1,772 shares at $94.81 and CFO Joan Hooper selling 962. All trades scored low on significance and occurred when the stock was above $94 — well above current levels — suggesting routine plan-based activity rather than a directional signal. Net insider activity over 90 days is positive at +116,852 shares, but the recent individual transactions lean sell.
Peers had a rough week too. VNT — the closest correlated name — dropped 3.6% on the week, offering little relative comfort. CLMB fell 6%. The weakness is broad across the electronic equipment space. What to watch now is whether the revised Street numbers — particularly JPMorgan's new $113 target — start to form a more realistic floor, or whether further estimate cuts follow the softer Q1 top line.
See the live data behind this article on ORTEX.
Open ITRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
